

**GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS AND FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA
UNSTARRED QUESTION NO. 2595
TO BE ANSWERED ON THE 04th August, 2023

Funds for Research & Development of New Drugs

2595. SHRI RAMESH CHAND BIND:

Will the Minister of **CHEMICALS AND FERTILIZERS** be pleased to state:

- (a) the details of the funds allocated for Research and Development of new drugs/vaccines in the country for the last three years, year-wise;
- (b) whether the Government has prepared any roadmap for pharma industry to reduce dependency for raw materials on foreign nations; and
- (c) if so, the details thereof?

ANSWER

**MINISTER OF STATE IN THE MINISTRY OF CHEMICALS & FERTILIZERS
(SHRI BHAGWANTH KHUBA)**

(a): Research & Development and innovation in the pharma sector is done by number of institutions and organisations under various Ministries/ Departments, which have their own budgetary provisions.

The Department of Pharmaceuticals (DoP) has set up seven National Institutes of Pharmaceutical Education & Research (NIPERs) as institutes of national importance, to nurture and promote quality and excellence in pharmaceutical education and research in India. The allocation for NIPERs over last three years including grants for building and Infrastructure as well as research and academic activities is given in table below.

Council of Scientific and Industrial Research (CSIR) under the Department of Scientific and Industrial Research (DSIR), through its constituent laboratories, has also been pursuing R&D activities for drug discovery and development. Further, Department of Biotechnology (DBT), along with its Public Sector Undertaking (PSU) Biotechnology Industry Research Assistance Council (BIRAC) has facilitated implementation of R&D projects for drug discovery in for research and development of new drugs/vaccines.

Allocation during the last three years for these schemes/ programmes are as under:

Financial year	NIPERs under DoP*	CSIR under DSIR	BIRAC under DBT
2020-21	Rs. 333.82 cr.	Rs. 24.64 cr.	Rs. 64.52 cr.
2021-22	Rs. 372.00 cr.	Rs. 101.37 cr.	Rs. 62.57 cr.
2022-23	Rs. 451.13 cr.	Rs. 74.79 cr.	Rs. 46.34 cr.

Department of Scientific & Technology (DST) has taken steps for development of therapeutic strategies for preventing rare/orphan disorders, for which Rs. 8.56 Cr. has been sanctioned during the current financial year.

(b) & (c): Government has launched Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India, with a financial outlay of Rs. 6,940 crores for a tenure from FY 2020-2021 to FY 2029-30. In addition, financial assistance for setting up Common Infrastructure Facilities (CIF) in three Bulk Drugs parks to the tune of Rs. 3,000 cr. for a tenure from FY 2020-21 to 2024-25, with Rs. 1,000 cr for each park, is being provided.
